NCT03048578View on ClinicalTrials.gov

Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

PHASE4CompletedINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

March 2, 2021

Study Completion Date

March 2, 2021

Conditions

Obesity

Interventions

DRUG

Saxenda

Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day

DRUG

Placebo

Subcutaneous Saline Solution

Trial Locations (1)

10016

New York University Medical Center, New York

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

NYU Langone Health

OTHER